Abbott launched a new DRG invisible trial system, a non-opioid pain therapy for people suffering from chronic pain. Later, patients with adequate pain relief can be implanted with Abbott’s Proclaim DRG system to manage their pain with Apple consumer technology. The system secured a CE (European Conformity) mark in Europe and is approved by the US Food and Drug Administration (FDA).
This DRG therapy can target the dorsal root ganglion (DRG), a structure adjacent to the spinal cord densely covered with sensory nerves that transmits chronic pain to the central nervous system.
The therapy enables to block pain signals with electrical pulses transmitted over the DRG in the patients with neuropathic pain conditions.
DRG therapy can offer better pain relief compared to traditional spinal cord stimulation (SCS) therapy for patients with persistent neuropathic focal pain conditions. A patient can use an Apple iPod touch, an Apple consumer device, to manage their pain relief for around a week. The new DRG invisible trial system is an extension to the invisible trial system for BurstDR stimulation.
“By enabling a temporary trial, people can test the treatment before receiving a permanent implant. If they experience meaningful pain relief, they can choose to move forward with our DRG therapy and find long-term pain relief—helping them live a fuller, healthier life again without relying on opioids,” said a statement from Abbot.